Posted by Michael Wonder on 25 Apr 2026
Novartis receives positive CHMP opinion for Itvisma for spinal muscular atrophy
24 April 2026 - Novartis today announced that the CHMP of the EMA has adopted a positive opinion recommending marketing authorisation for Itvisma (intrathecal onasemnogene abeparvovec).
The opinion supports its use for the treatment of children two years and older, teens, and adults living with 5q spinal muscular atrophy with a bi-allelic mutation in the survival motor neuron 1 gene.
